A new market study, titled “Global Neuroendocrine Tumours Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023”, has been featured on WiseGuyReports.
Global Neuroendocrine Tumours Therapeutics Market
Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body. Most neuroendocrine tumours occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands.
Neuroendocrine tumours therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumours are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuro endocrine tumours. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumours in developing regions is anticipated to drive global neuroendocrine tumours market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumours market.
The global neuroendocrine tumours therapeutics market is segmented on the basis of the indication, distribution channel, drug class, and geographical regions.
Based on indication, global neuroendocrine tumours therapeutics market is segmented as
Based on distribution channel, global neuroendocrine tumour treatment market is segmented as:
Based on therapy, global neuroendocrine tumour treatment Market is segmented as
The neuroendocrine tumour treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumours by treating with various medications are expected to have a positive impact on neuroendocrine tumours market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.
Based on the geographical regions, global neuroendocrine tumours market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumours therapeutics market are based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumours therapeutics market. Europe is the second largest market for neuroendocrine tumours therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.
Some of the players operating in the global neuroendocrine tumours therapeutics market include Pfizer Inc., (U.S), Eli Lilly & Company (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd.(Switzerland), Ipsen (France), Amgen, Inc. (U.S.), Teva Pharmaceuticals, Ltd. (Israel), and Bristol-Myers Squibb (U.S.).
In 2016, Novartis received the U.S. FDA approval for its Afinitor®(everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin
In 2014, Ipsen Biopharmaceuticals, Inc., received U.S.FDA approval for Somatuline®Depot® (lanreotide) Injection 120 mg to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients
The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Table of Content
- Executive summary
- Global Neuroendocrine Tumors Therapeutics Market Introduction
- Global Neuroendocrine Tumors Therapeutics Market Dynamics
- Global Neuroendocrine Tumors Therapeutics Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
- Global Neuroendocrine Tumors Therapeutics Market, By Drug Class, 2012 – 2016 and Forecast, 2017 – 2023
- Global Neuroendocrine Tumors Therapeutics Market Forecast, By Indication, 2012 – 2016 and Forecast, 2017 – 2023
- Global Neuroendocrine Tumors Therapeutics Market Forecast, By Distribution Channel, 2012 – 2016 and Forecast, 2017 – 2023
- Global Neuroendocrine Tumors Therapeutics Market Forecast, By Region, 2012 – 2016 and Forecast, 2017 – 2023
- North America Neuroendocrine Tumors Therapeutics Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
- Europe Neuroendocrine Tumors Therapeutics Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
- Asia-Pacific Neuroendocrine Tumors Therapeutics Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
- Latin America Neuroendocrine Tumors Therapeutics Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
- Middle East and Africa Neuroendocrine Tumors Therapeutics Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023
- Competition Landscape
- Research Methodology
- Key Assumptions and Acronyms
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)